
|Articles|October 24, 2012
Intranasal fentanyl spray benefits compared with oral agents for breakthrough cancer pain
Patients with breakthrough cancer pain (BTCP) may want to consider intranasal fentanyl spray over oral agents to treat their breakthrough pain because of improved onset of analgesia and avoidance of nausea and vomiting, according to a report published online September 25 for The Annals of Pharmacotherapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FAQ: The Medicare GLP-1 Bridge—What Independent Pharmacists Need to Know
2
Strategies to Drive Pharmacy Sustainability in a Changing Landscape
3
Grocery Pharmacy Conglomerate to Pay $40 Million for Violating False Claims Act
4
Machine Learning Can Identify Immune Markers for Better Pneumococcal Vaccines
5



































